Table 4.
Univariable Analyses of Covariables Associated with Overall Survival
| Factors | HR | 95% CI | P-value |
|---|---|---|---|
| Group | |||
| Targeted-radiotherapy vs Radiotherapy-targeted | 0.636 | 0.341–1.187 | 0.156 |
| Age at BM (y) | |||
| ≤50 vs > 50 | 0.910 | 0.487–-1.697 | 0.766 |
| KPS | |||
| ≥ 90 vs < 90 | 1.038 | 0.533–2.022 | 0.913 |
| Number of BM | |||
| 1–3 vs > 3 | 1.502 | 0.807–2.795 | 0.199 |
| Time from the first diagnosis to BM (m) | |||
| ≥ 29 vs < 29 | 0.585 | 0.314–1.091 | 0.092 |
| Molecular subtype (n) | |||
| Luminal B (HER2+) vs HER2 overexpression | 1.141 | 0.611–2.132 | 0.678 |
| Treatment of Primary breast disease (Targeted therapy) | |||
| Yes vs No | 0.758 | 0.372–1.548 | 0.447 |
| Primary surgical treatment | |||
| Yes vs No | 1.881 | 0.982–3.605 | 0.057 |
| Ki-67 | |||
| ≥ 14 vs < 14 | 0.905 | 0.375–2.179 | 0.823 |
| Treatment after BM | |||
| Endocrine therapy | |||
| Yes vs No | 0.580 | 0.221–1.523 | 0.269 |
| Chemotherapy | |||
| Yes vs No | 0.566 | 0.199–1.611 | 0.286 |
Abbreviations: HR, hazard ratio; CI, confidence interval; OS, overall survival; BM, brain metastasis; KPS, Karnofsky performance status; HER2, human epidermal growth factor receptor 2.